These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28619439)

  • 21. Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
    Uribe-Noguez LA; Ocaña-Mondragón A; Mata-Marín JA; Cázares-Cortázar A; Ribas-Aparicio RM; Gómez-Torres ME; Gaytán-Martínez J; Martínez-Rodríguez ML
    J Infect Chemother; 2018 Nov; 24(11):928-931. PubMed ID: 29773440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program.
    Karchava M; Chkhartishvili N; Sharvadze L; Abutidze A; Dvali N; Gatserelia L; Dzigua L; Bolokadze N; Dolmazashvili E; Kotorashvili A; Imnadze P; Gamkrelidze A; Tsertsvadze T
    Hepatol Res; 2018 Jan; 48(1):36-44. PubMed ID: 28258606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b.
    Raghwani J; Thomas XV; Koekkoek SM; Schinkel J; Molenkamp R; van de Laar TJ; Takebe Y; Tanaka Y; Mizokami M; Rambaut A; Pybus OG
    J Virol; 2012 Feb; 86(4):2212-20. PubMed ID: 22114341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    Abdallah F; Mohamed G; Ibrahim M; El Tarabily M
    Am J Med Sci; 2018 May; 355(5):456-466. PubMed ID: 29753376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants].
    Yushchuk ND; Znoyko OO; Dudina KR; Kozina AN; Kalininа OV
    Ter Arkh; 2016; 88(6):101-105. PubMed ID: 27489903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
    Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
    Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains.
    Trémeaux P; Caporossi A; Ramière C; Santoni E; Tarbouriech N; Thélu MA; Fusillier K; Geneletti L; François O; Leroy V; Burmeister WP; André P; Morand P; Larrat S
    Clin Microbiol Infect; 2016 May; 22(5):460.e1-460.e10. PubMed ID: 26827671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
    Haqqi A; Munir R; Khalid M; Khurram M; Zaid M; Ali M; Shah ZH; Ahmed H; Afzal MS
    Viral Immunol; 2019 Nov; 32(9):402-413. PubMed ID: 31556811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    Mourez T; Decroos A; Goria O; Montialoux H; De Oliveira F; Larrat S; Plantier JC; Riachi G
    J Med Virol; 2018 May; 90(5):994-997. PubMed ID: 29350410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.